Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|B-Cell Non-Hodgkin Lymphomas(NHL)
DRUG: SHC014748M
Dose Limiting Toxicity (DLT), 1 month|Time to Peak Plasma Concentration（Tmax）, 1 month|Peak Plasma Concentration (Cmax), 1 month|Half-life Time(t1/2), 1 month|Area Under the Plasma Concentration Versus Time Curve (AUC), 1 month
Objective Response Rate (ORR), up to 12 months|Lymph Node Response (LNR), up to 12 months|Time to Response (TTR), up to 12 months|Progression-Free Survival (PFS), up to 12 months|Duration of Response (DOR), up to 12 months
This is a phase I, sequential dose escalation followed by cohort expansion study of SHC014748M, an oral inhibitor of PI3K delta, in patients with relapsed or refractory indolent B-cell hematologic malignancies.